Back to Archived News
USPTO Issues Notice of Allowance for Additional MultiStat Patent
Thursday, June 17, 2010
Forthcoming Patent Covers Methods for Treating Rosacea
Gainesville, FL -- Quick-Med Technologies, Inc. (OTCBB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that extends the current patent coverage for the Company's MultiStat® family of compounds. The forthcoming patent is part of a portfolio that Quick-Med has licensed from the University of Michigan.
The Notice of Allowance covers patent claims that address methods for treating rosacea with an antimicrobial, a retinoid, and an inhibitor of toll-like receptors in both topical and oral applications. The broad range of antimicrobials to be utilized in combination with the MultiStat family includes tetracycline, erythromycin, azithromycin, clarithromycin, milbemycin, aminoglycoside, penicillin (optimally in combination with a beta-lactamase inhibitor), cephalosporin, fluoroquinolone, streptogramin and sulfanomide.
"Our MultiStat technology has shown to have significant benefit in promoting the maintenance, healing and repair of skin," said J. Ladd Greeno, Quick-Med's CEO. "We are pleased the patent office has issued this Notice of Allowance as it not only strengthens our intellectual property for the cosmetic treatment of rosacea but also adds to our MultiStat patent estate."
A Notice of Allowance communicates the Patent Office's determination that the applicant is entitled to a patent under the law. The Company expects the new patent to be issued later this year.
MultiStat® is Quick-Med's family of patented matrix metalloproteinase inhibitors (MMPIs), which have been shown to be highly effective in reducing skin wrinkling and aging. The MultiStat family consists of 10 patented compounds, patented formulae for developing other compounds, numerous use or method patents and other intellectual property involving the use of MMP inhibition techniques in skin therapy. These MMPIs, which have been proven effective in broad-based applications, including improving the appearance of fine lines and wrinkles associated with natural aging or sun-induced premature aging and damage, are marketed to the cosmetics industry as performance ingredients in commercially available anti-aging creams. Quick-Med currently owns or has exclusive licenses for topical uses of MultiStat compounds for cosmetic and military applications.
Rosacea is a chronic skin condition involving inflammation of the cheeks, nose, chin, forehead, or eyelids. It may appear as redness, prominent spider-like blood vessels, swelling, or skin eruptions similar to acne. According to the National Rosacea Society an estimated 16 million Americans currently suffer from rosacea.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. For more information, see: www.quickmedtech.com.
© 2010 Quick-Med Technologies, Inc. All rights reserved. MultiStat® is a registered trademark of Quick-Med Technologies, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.
Back to Archived News